Top News in R&D
 
 

 

 

READ ONLINE

 

 
 
 
 Global Health Technologies Coalition 
 
 
 
 

 

R&D News Roundup: March 20, 2023

 

Top News in R&D

Dengue treatment advances in animal trials
France24 (3/16), features Johnson & Johnson

A research team from Johnson & Johnson has refined and tested a new dengue treatment with promising results in animal studies. The treatment was tested for prevention and treatment in mice and for prevention in monkeys. No treatment exists for dengue, which has four different strains, and the two available vaccines for the disease have not yet been approved universally, highlighting the great potential of this new treatment in reducing disease burden. Further research is needed to find out whether the treatment could produce vulnerability to more serious reinfection and to test the compound in humans.

WHO recommends new malaria bed nets to fight resistant parasites
Devex (3/15)
Additional coverage from The Telegraph (3/15)

Last week, the World Health Organization (WHO) recommended the use of bednets treated with new insecticides in areas where there is mosquito resistance to pyrethroid, which has historically been used to treat bednets. WHO now recommends combining pyrethroid with an additional chemical—either the insect growth regulator pyriproxyfen or the insecticide chlorfenapyr. The recommendations are based on large-scale trials done by the London School of Hygiene & Tropical Medicine in Tanzania and Benin. Researchers say the rollout of the new bednets could happen as early as the next few months and should take place in concert with the development of a comprehensive long-term plan to manage and prevent future resistance.

BioNTech mobile mRNA vaccine labs reach Rwanda
MedicalXpress (3/13)

Mobile vaccine production units, made by German pharmaceutical company BioNTech, recently arrived in Rwanda as part of a larger initiative to boost mRNA vaccine manufacturing on the African continent. The facility, which will hopefully start producing doses in around a year, will be able to manufacture up to 100 million mRNA vaccines a year for African Union countries, as well as potentially innovate treatments for diseases like HIV/AIDS, tuberculosis, and malaria, which are among the leading causes of death on the continent. There are further deliveries of these mobile production units planned for South Africa and Senegal.

 

 

News from GHTC

 

 

Highlights From the Week

 

 

COVID-19 R&D spotlight

 

 

Upcoming Events

March 23
Malaria vaccine webinar
Virtual

June 13-15
Vaccine Acceptance Research Network 2023
Bangkok, Thailand

October 18-22
ASTMH 2023 Annual Meeting
ASTMH

December 5-7
13th International Conference on Typhoid & Other Invasive Salmonelloses
Sabin Vaccine Institute